March 9, 2021 4:55pm

After being grossly oversold, it was not surprising to see the bounce skyward

Pre-open indication results: 11 HITs and 1 MISS

Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence


The Dow closed UP +30.30 points (+0.10%); the S&P closed UP +54.09 points (+1.42%) while the Nasdaq closed UP +464.66 points (+3.69%)



Indexes jumped sharply on Tuesday after bond yields declined, causing investors to buy the dip in cell and gene therapy equities.


RegMed Investors’ (RMi) pre-open: “BUY opportunities post sell-off, earnings are still being released” …


Pre-open indication results:  11 HITs <SELL: Biostage (BSTG -$0.10 with 1,254 shares); Bellicum Pharmaceuticals (BLCM +$0.38), Applied Genetic Technologies (AGTC +$0.52), bluebird bio (BLUE +$2.94), Cellectis SA (CLLS +$3.37), Homology Medicine (FIXX +$0.63), Intellia Therapeutics (NTLA +$10.55), CRISPR Therapeutics (CRSP +$12.01), Editas Medicine (EDIT +$4.79), Fate Therapeutics (FATE +$9.36), Global Blood therapeutics (GBT +$2.89), Sangamo Therapeutics (SGMO +$0.64) and 0 MISS


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Tuesday opened positive at 30/2 2 flat and 1 acquired, stayed positive at the mid-day to 31/3 and 1 acquired, closing positive at 30/4 and 1 acquired;


There are clear winners and losers

Jumping with share pricing momentum:

  • Ultragenyx (RARE), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Fate Therapeutics (FATE), Editas Medicine (EDIT) to name 5 of the 30 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), MiMedx (MDXG), Alnylam Pharmaceuticals (ALNY -$0.31), Biostage (BSTG) to name 4 of the 4 declining of the 35 covered


Key metrics:

  • Sector volume was LOW with 7 of the 30-upside having higher than the 3-month average volume with the volume of 2 of 4-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 30-upside were +0.92% (MESO) to +22.64% (NTLA) while the 4-downside ranges from -0.68% (ALNY) to -9.73% (MDXG);


Tuesday’s (10 of 30) incline

  • CRISPR Therapeutics (CRSP +$12.01);
  • Intellia Therapeutics (NTLA +$10.55 after Monday’s -$5.22);
  • Fate Therapeutics (FATE +$9.36 after Monday’s -$4.49);
  • Ultragenyx (RARE +$9.22 after Monday’s -$3.50);
  • Editas Medicine (EDIT +$4.79 after Monday’s -$1.09
  • Cellectis SA (CLLS +$3.37 after Monday’s +$0.05);
  • Sage Therapeutics (SAGE +$2.98 after Monday’s -$2.08);
  • BioLife Solutions (BLFS +$2.94 after Monday’s -$2.37);
  • Global Blood Therapeutics (GBT +$2.89 after Monday’s -$2.02);
  • Regenxbio (RGNX +$2.54);

Tuesday’s (4 of 4) decliners:

  • ReNeuron (RENE.L -$1.00);
  • MiMedx (MDXG -$0.97);
  • Alnylam Pharmaceuticals (ALNY -$0.94 after Monday’s -$4.77);
  • Biostage (BSTG -$0.10 after Monday’s -$0.03);

Closing 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • The Senate approval of the $1.9 trillion economic relief and stimulus bill had prompted investors to continue to rotate into reopening plays and cyclical stocks to bet on a sharp economic rebound as vaccinations increase geographically.

Infection cases <Million>: never to forget …

  • Tuesday 29.04 M cases,
  • Tuesday’s death rate totaled 525,904 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +2.94% and XBI closed up +4.65%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -1.44 points or -5.65% at 24.03

Upside volume: low

  • Tuesday: 7 out of the 30-upside had higher than the 3-month average volume;

Downside volume: low

  • Tuesday: 2 out of the 4-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Tuesday’s percentage (%) of the 30-upside were +0.92% (MESO) to +22.64% (NTLA) while the 4-downside ranges from -0.68% (ALNY) to -9.73% (MDXG);


March, the 3rd month of Q1/21:

Tuesday closed positive with 30 advancers, 4 decliners and 1 acquired


The BOTTOM LINE: What went down, went up as the algorithms lead the way …

Sustainability is the real issue in “this” market!

Markets are scary, frightening investors – volatilities basis is pure speculation i.e., gambling.

NOT for me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.

There is always a shift going-on however, these last two (2) months and one (1) week continues to leave me … QUESTIONING each WEEK as I have said recently - my horizon on Monday is to meet on Friday.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice has been … trim and skim … if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.